Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated with chronic kidney disease, which led to the development of therapeutic agents for treatment. A new class of agents for the treatment of anemia in chronic kidney disease are prolyl hydroxylase inhibitors, which stabilize hypoxia-inducible factor that is the key regulator of erythropoiesis and iron metabolism. Currently, drugs such as roxadustat (FG-4592), vadadustat (AKB-6548), daprodustat (GSK1278863) are undergoing phase III clinical trials, and molidustat (BAY 85-3934) — phase II.
anemia; chronic kidney disease; hypoxia-inducible factor; prolyl hydroxylase inhibitor; roxadustat; vadadustat; daprodustat; molidustat; review
Full Text:PDF (Русский)
Copyright (c) 2018 KIDNEYS
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020